Casticin as potential anticancer agent: recent advancements in multi-mechanistic approaches

Basit Öğe Kaydı
dc.authoridCalina, Daniela/0000-0002-1523-9116
dc.authoridSharifi-Rad, Javad/0000-0002-7301-8151
dc.contributor.authorCarbone, Katya
dc.contributor.authorGervasi, Fabio
dc.contributor.authorKozhamzharova, Latipa
dc.contributor.authorAltybaeva, Nazgul
dc.contributor.authorGurer, Eda Sonmez
dc.contributor.authorSharifi-Rad, Javad
dc.contributor.authorHano, Christophe
dc.date.accessioned2024-10-26T18:11:10Z
dc.date.available2024-10-26T18:11:10Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPlants, with their range of pharmacologically active molecules, represent the most promising source for the production of new anticancer drugs and for the formulation of adjuvants in chemotherapy treatments to reduce drug content and/or counteract the side effects of chemotherapy. Casticin is a major bioactive flavonoid isolated from several plants, mainly from the Vitex species. This compound is well known for its anti-inflammatory and antioxidant properties, which are mainly exploited in traditional medicine. Recently, the antineoplastic potential of casticin has attracted the attention of the scientific community for its ability to target multiple cancer pathways. The purpose of this review is, therefore, to present and critically analyze the antineoplastic potential of casticin, highlighting the molecular pathways underlying its antitumor effects. Bibliometric data were extracted from the Scopus database using the search strings casticin and cancer and analyzed using VOSviewer software to generate network maps to visualize the results. Overall, more than 50% of the articles were published since 2018 and even more recent studies have expanded the knowledge of casticin's antitumor activity by adding interesting new mechanisms of action as a topoisomerase IIa inhibitor, DNA methylase 1 inhibitor, and an upregulator of the onco-suppressive miR-338-3p. Casticin counteracts cancer progression through the induction of apoptosis, cell cycle arrest, and metastasis arrest, acting on several pathways that are generally dysregulated in different types of cancer. In addition, they highlight that casticin can be considered as a promising epigenetic drug candidate to target not only cancer cells but also cancer stem-like cells.
dc.identifier.doi10.3389/fmolb.2023.1157558
dc.identifier.issn2296-889X
dc.identifier.pmid37304067
dc.identifier.scopus2-s2.0-85161375663
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3389/fmolb.2023.1157558
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30550
dc.identifier.volume10
dc.identifier.wosWOS:001004423900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers in Molecular Biosciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectcasticin
dc.subjectVitex spp
dc.subjectcancer
dc.subjectmolecular mechanisms
dc.subjectsignaling pathways
dc.subjectapoptosis
dc.titleCasticin as potential anticancer agent: recent advancements in multi-mechanistic approaches
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu